The Mixed Lineage Leukemia (MLL) gene codes for a histone methyltransferase that is frequently mutated by chromosomal translocations in human leukemias associated with a poor clinical outcome. The studies proposed in this competitive renewal application address the hypothesis that the leukemogenic actions of MLL oncoproteins are critically dependent on proteins recently discovered to associate with MLL or its fusion partners, and that the activities or interactions of these associated factors constitute potential targets for molecular therapies. This hypothesis is based on major discoveries during the current award period that have substantially advanced our understanding of the molecular mechanisms of MLL leukemias. We have shown that menin, a tumor suppressor protein and MLL- associated factor, is paradoxically required for MLL-mediated leukemogenesis. Menin functions as a transcriptional co-factor for MLL oncoproteins, and in this capacity we demonstrated that its only role is to promote interactions with a newly discovered MLL- associated protein known as LEDGF/p75. The latter is a chromatin-associated protein with co-activator activity but unknown molecular function, previously implicated in leukemia and HIV pathogenesis. Studies in the first specific aim will characterize the molecular functions of LEDGF/p75 required for MLL-mediated leukemogenesis using biochemical and genetic approaches in pre-clinical and cell line transformation model systems. These studies will identify a potential ligand for the putative methyl-lysine recognition motif of LEDGF/p75 and also establish the feasibility of antagonizing their interactions as a molecular therapeutic strategy. Studies in the second aim will employ genetic and biochemical techniques to determine the molecular mechanisms that underlie oncogenic activation of LEDGF/p75 itself by chromosomal translocations in leukemias, and establish its specific roles in leukemogenesis mediated through the MLL and/or Myc transcriptional pathways. Studies in the third specific aim are based on our discovery of a multi-protein complex (AEP) that contains several MLL fusion partners and the P-TEFb transcription elongation factor. This novel complex is tethered by a subset of MLL oncoproteins to critical target genes in MLL leukemia cells, however its molecular contributions required for leukemogenesis have not been fully defined. Our studies will further characterize the AEP complex, its critical enzymatic activities, its implications for MLL transcriptional regulation in general, and its role in MLL-mediated leukemogenesis. The therapeutic value of targeting the activities or interactions of AEP components with pathogenic roles in MLL leukemia will be interrogated using preclinical transformation models.

Public Health Relevance

This application proposes to investigate the critical molecular processes that cause cancers of blood-forming cells. Highly refined genetic and biochemical model systems will be employed to study cancer-associated pathways in normal stem cells as well as their cancerous counterparts and progeny. A greater understanding of the similarities and differences among normal and cancer stem cells will facilitate efforts to selectively target the latter while sparing the former to achieve more efficacious therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA116606-10
Application #
8659348
Study Section
Hematopoiesis Study Section (HP)
Program Officer
Mufson, R Allan
Project Start
2005-08-05
Project End
2015-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
10
Fiscal Year
2014
Total Cost
$296,000
Indirect Cost
$114,516
Name
Stanford University
Department
Pathology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Duque-Afonso, Jesús; Cleary, Michael L (2014) The AML salad bowl. Cancer Cell 25:265-7
Yokoyama, Akihiko; Ficara, Francesca; Murphy, Mark J et al. (2013) MLL becomes functional through intra-molecular interaction not by proteolytic processing. PLoS One 8:e73649
Kuo, Hsu-Ping; Wang, Zhong; Lee, Dung-Fang et al. (2013) Epigenetic roles of MLL oncoproteins are dependent on NF-*B. Cancer Cell 24:423-37
Yokoyama, Akihiko; Ficara, Francesca; Murphy, Mark J et al. (2011) Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J Cell Sci 124:2208-19
Chang, Pei-Yun; Hom, Robert A; Musselman, Catherine A et al. (2010) Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol 400:137-44
Hom, Robert A; Chang, Pei-Yun; Roy, Siddhartha et al. (2010) Molecular mechanism of MLL PHD3 and RNA recognition by the Cyp33 RRM domain. J Mol Biol 400:145-54
Yokoyama, Akihiko; Lin, Min; Naresh, Alpana et al. (2010) A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17:198-212
Wang, Zhong; Iwasaki, Masayuki; Ficara, Francesca et al. (2010) GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17:597-608
Wong, Piu; Iwasaki, Masayuki; Somervaille, Tim C P et al. (2010) The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 70:3833-42
Somervaille, Tim C P; Matheny, Christina J; Spencer, Gary J et al. (2009) Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4:129-40

Showing the most recent 10 out of 13 publications